- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04013048
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
July 30, 2020 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase I Mass Balance and Biotransformation Study of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-FZPL in Chinese Patients with Solid Tumor
Study Overview
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital of Soochow University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects diagnosed with advanced solid malignancies who are refractory or intolerant to standard therapy or considered to be benefit from the treatment of fluzoparib.
- ECOG performance status of 0 to 1.
- Life expectancy of more than 3 months.
- Signing the informed consent forms.
- Adequate bone marrow, liver and renal function.
- Be able to communicate well with the researcher and be able to complete the trial in accordance with the program.
Exclusion Criteria:
- Subjects who take any drugs that strongly inhibit or induce the CYP450 enzyme 14 days prior to study drug administration;
- Those who have history of alcohol abuse (it was defined as that the daily alcohol consumption was higher than the following criteria: the weekly alcohol consumption was higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40% alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath test results ≥20 mg/dl during screening period;
- Subjects who smoked daily >5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study.
- Subjects who have history of drug abuse or taking soft drug (i.e., marihuana) 3 months prior to screening period or taking hard drugs (i.e., cocaine, amphetamines, benzodiazepine, etc.); or the results of urine test in drugs were positive.
- Subjects who were used to drink grapefruit juice or overconsumption of tea, coffee, and the drink with caffeine; and cannot give up them during test.
- Subjects who need long-term exposure to radiation, or who have been exposed to PET-CT or ECT within 3 months prior to study drug administration or who have participated in the labeling test of radiopharmaceuticals.
- Subjects who have fertility planning within the range of starting trial - 1 year after finishing trial.
- Subjects who have excessive bleeding or blood donation (400ml) 3 months prior to screening period, or planned to donate blood 1 month after finishing this trial.
- Subjects who have habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
- Subjects must not have had prior treatment with PARP inhibitors.
- Subjects who cannot complete this study because of other reasons, or any factors judged by investigator that the participants cannot meet.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]-Fluzoparib
Patients will receive single dose of [14C]- Fluzoparib.
|
Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The distribution of Fluzoparib in the whole blood and plasma and whole.radioactive pharmacokinetics following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.
Time Frame: Up to 10 days (approx) from the start of administration.
|
The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in blood and in total, up to Day 10 (approx).
|
Up to 10 days (approx) from the start of administration.
|
Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor to obtain the mass balance data and the main excretion pathway in human body.
Time Frame: Up to 10 days (approx) from the start of administration.
|
The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in urine, faeces and in total, up to Day 10 (approx).
|
Up to 10 days (approx) from the start of administration.
|
Identification of the main metabolite and biotransformation pathway of Fluzoparib and investigation of metabolite with proportion >10% in plasma following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.
Time Frame: Up to 10 days (approx) from the start of administration.
|
Proportion of different metabolites.
|
Up to 10 days (approx) from the start of administration.
|
Quantitive analysis of the concentrations of Fluzoparib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.
Time Frame: Up to 10 days (approx) from the start of administration.
|
The concentrations of Fluzoparib in plasma up to Day 10.
|
Up to 10 days (approx) from the start of administration.
|
Observation of safety following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.
Time Frame: Up to 10 days (approx) from the start of administration.
|
Adverse events assessed by CTCAE v5.0.
|
Up to 10 days (approx) from the start of administration.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2019
Primary Completion (Actual)
December 24, 2019
Study Completion (Actual)
December 24, 2019
Study Registration Dates
First Submitted
July 7, 2019
First Submitted That Met QC Criteria
July 7, 2019
First Posted (Actual)
July 9, 2019
Study Record Updates
Last Update Posted (Actual)
July 31, 2020
Last Update Submitted That Met QC Criteria
July 30, 2020
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FZPL-I-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
Clinical Trials on [14C]-Fluzoparib
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced HER2 Negative Breast Carcinoma | HRD+Breast CancerChina
-
wang shusenRecruitingAdvanced HER2 Negative Breast Carcinoma HRD+Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Peking University People's HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Enrolling by invitationGermline BRCA-mutated HER2-negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.307 Hospital of PLA; Peking University Cancer Hospital & InstituteCompletedAdvanced Solid MalignanciesChina
-
Atridia Pty Ltd.Completed
-
Atridia Pty Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSmall Cell Lung CancerChina